1012341-48-8

E)-5-([1 (R,E)-5-([1,1'-BiphenyL )-4-((tert-butoxycarbonyL LCZ696(valsartan + sacubitril) impurity 30 (R,E)-5-(biphenyl-4-yl)-4-(tert-butoxycarbonylamino) 5-Biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methyl-pent-2-enoic acid 1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoic acid (R,E)-5-(biphenyl-4-yl)-4-(tert-butoxycarbonylamino)-2-methylpent-2-enoic acid (R,E)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoic acid (2E,4R)-5-{[1,1'-biphenyl]-4-yl}-4-{[(tert-butoxy)carbonyl]amino}-2-methylpent-2-enoic acid (E,4r)-2-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-(4-phenylphenyl)pent-2-enoic acid (R, E) -5-([1,1'-Biphenyl] -4-yl) -4-((tert-butoxycarbonyl) amino) -2-methyl-2-pentenoic acid (2E,4R)-5-[1,1'-biphenyl]-4-yl-4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methyl-2-Pentenoic acid 2-Pentenoic acid, 5-[1,1'-biphenyl]-4-yl-4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methyl-, (2E,4R)- (2E,4R)-5-[1,1'-Biphenyl]-4-yl-4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methyl-2-pentenoic acid AHU83 (R,E)-5-([1,1'-Biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpent-2-enoic acid (LCZ696 Impurity) LCZ696 intermediates，(R,E)-5-([1,1'-biphenyl]-4-yl)-4-((tert- butoxycarbonyl)aMino)-2-Methylpent- 2-enoic acid (R,E)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoic acid###1012341-48-8 enantioMer